<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of sporotrichosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of sporotrichosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of sporotrichosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carol A Kauffman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen B Calderwood, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheldon L Kaplan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 06, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sporotrichosis is a subacute to chronic infection caused by the dimorphic fungus
         <em>
          Sporothrix schenckii
         </em>
         . Infection usually involves cutaneous and subcutaneous tissues but can occasionally occur in other sites, primarily in immunocompromised patients. Activities associated with the development of sporotrichosis include landscaping, rose gardening, and other activities that involve inoculation of soil through the skin.
        </p>
        <p>
         Treatment of sporotrichosis varies with the type of disease [
         <a href="#rid1">
          1
         </a>
         ]. Since most manifestations are subacute to chronic and localized, oral antifungal agents are usually preferred. The agent of choice is
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         [
         <a href="#rid2">
          2
         </a>
         ]. The rare cases of life-threatening, visceral, or disseminated infection require therapy with intravenous amphotericin B, which is also used in patients who do not respond to itraconazole.
        </p>
        <p>
         The treatment of the various manifestations of sporotrichosis will be reviewed. The approach is consistent with the 2007 Infectious Diseases Society of America clinical practice guidelines for the management of sporotrichosis  (
         <a class="graphic graphic_table graphicRef50353" href="/z/d/graphic/50353.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The basic biology, epidemiology, clinical manifestations, and diagnosis of sporotrichosis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2433.html" rel="external">
          "Basic biology and epidemiology of sporotrichosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2457.html" rel="external">
          "Clinical features and diagnosis of sporotrichosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CHOICE OF ANTIFUNGAL AGENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of antifungal agent in patients with sporotrichosis is limited. In vitro susceptibility studies and clinical experience support
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         as the treatment of choice for patients with most forms of localized sporotrichosis, and amphotericin B as the preferred treatment for patients who are severely ill [
         <a href="#rid3">
          3-5
         </a>
         ].
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          Fluconazole
         </a>
         and
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         are poor second-line choices [
         <a href="#rid6">
          6-8
         </a>
         ]. More detailed information on the use of these agents (eg, monitoring and side effects) is found in the Lexicomp drug information topics within UpToDate and in separate topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/476.html" rel="external">
          "Pharmacology of amphotericin B"
         </a>
         .)
        </p>
        <p>
         In vitro studies have demonstrated good activity for
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         , and the minimum inhibitory concentration for
         <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">
          terbinafine
         </a>
         is low for most isolates [
         <a href="#rid4">
          4,5,9-11
         </a>
         ]. Posaconazole has also been shown to be effective in a murine model of sporotrichosis [
         <a href="#rid12">
          12
         </a>
         ] and has been used successfully to treat a cat [
         <a href="#rid13">
          13
         </a>
         ]. There have also been a few reports of patients who were treated successfully with this agent [
         <a href="#rid14">
          14-16
         </a>
         ]. Several reports have found that
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         has poor activity in vitro [
         <a href="#rid4">
          4,5,9
         </a>
         ]. In addition,
         <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">
          isavuconazole
         </a>
         does not appear very active in vitro against
         <em>
          S. schenckii
         </em>
         [
         <a href="#rid17">
          17
         </a>
         ]; however, only a small number of isolates have been studied.
        </p>
        <p>
         One study established epidemiologic cutoff values to help define susceptibility to various antifungal agents by pooling data from 17 different laboratories (301
         <em>
          S. schenckii
         </em>
         sensu stricto and 486
         <em>
          S. brasiliensis
         </em>
         isolates were collected worldwide) [
         <a href="#rid18">
          18
         </a>
         ]. The most active agents for both species were
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         ;
         <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">
          terbinafine
         </a>
         was also active, but too few data were available to calculate a cutoff value for this agent for either species.
        </p>
        <p class="headingAnchor" id="H623574251">
         <span class="h1">
          APPROACH TO TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         This section will focus on the management of nonpregnant adults. Additional considerations for the management of pregnant persons and children are discussed below.(See
         <a class="local">
          'Additional considerations'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Lymphocutaneous and cutaneous sporotrichosis
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment
         </strong>
         –
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          Itraconazole
         </a>
         is the drug of choice for the treatment of lymphocutaneous and cutaneous sporotrichosis  (
         <a class="graphic graphic_table graphicRef50353" href="/z/d/graphic/50353.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1-3,19,20
         </a>
         ]. The usual dose is 100 to 200 mg/day orally, and treatment should be continued for two to four weeks after all lesions have resolved, usually for a total of three to six months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The success rate of this regimen based upon observational studies is 90 to 100 percent [
         <a href="#rid2">
          2,20,21
         </a>
         ]. We favor the 200 mg dose, since some patients will not respond to the lower dose and will require dose escalation. However, in a report about an established epidemic of sporotrichosis associated with exposure to cats in Rio de Janeiro, Brazil, a high rate of success was observed with the 100 mg dose [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="local">
          'Choice of antifungal agent'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients who do not respond to initial therapy
         </strong>
         – Patients who don't respond to
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         at 200 mg/day should be treated with one of the following alternatives:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          Itraconazole
         </a>
         200 mg orally twice daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">
          Terbinafine
         </a>
         at high doses (500 mg twice daily). This regimen appears to be effective for sporotrichosis, but few patients have been treated to date [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Saturated solution of potassium iodide (SSKI). The initial dose is five drops in juice or milk three times daily, increasing weekly, as tolerated, to a maximum of 40 to 50 drops in juice or milk three times daily. A once-daily regimen using the same total daily dosage has also been shown to be effective in children and may help improve compliance [
         <a href="#rid23">
          23
         </a>
         ]. Side effects include nausea, rash, metallic taste, fever, and salivary gland swelling.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         SSKI had been the preferred treatment until the 1990s, and in some countries it is still used as standard treatment for lymphocutaneous sporotrichosis [
         <a href="#rid23">
          23-25
         </a>
         ]. Although therapy with SSKI is difficult for most patients, it is much less costly than
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          Fluconazole
         </a>
         is considered a poor second-line therapy, but if necessary, should be used at a dose of 400 to 800 mg daily [
         <a href="#rid3">
          3,6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          If preferred agents are contraindicated
         </strong>
         – Local hyperthermia, induced by a variety of different warming devices or baths, has been used successfully and with minimal side effects for cutaneous sporotrichosis [
         <a href="#rid1">
          1,26
         </a>
         ]. Heat therapy could be used, for example, in a pregnant patient who has cutaneous sporotrichosis and cannot safely be treated with any of the oral drugs that are useful for sporotrichosis. (See
         <a class="local">
          'Treatment of pregnant persons'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Pulmonary sporotrichosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary sporotrichosis is difficult to treat, perhaps due to delayed diagnosis or underlying illnesses in infected patients [
         <a href="#rid2">
          2,3,6,24,27-29
         </a>
         ]. In addition to antifungal therapy, surgical resection should be considered, especially for those patients who have a single cavitary lesion [
         <a href="#rid29">
          29
         </a>
         ]. Saturated solution of potassium iodide (SSKI), which has efficacy in lymphocutaneous and cutaneous disease, has not been effective for pulmonary sporotrichosis. Outcomes have improved in recent years, but the response rates are still only about 50 percent.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Severe or life-threatening disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the patient is seriously ill, amphotericin B should be used initially; if not, then oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         can be given at a dose of 200 mg twice daily  (
         <a class="graphic graphic_table graphicRef50353" href="/z/d/graphic/50353.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'Choice of antifungal agent'
         </a>
         above.)
        </p>
        <p>
         When amphotericin B is used, a lipid formulation is preferred at a dose of 3 to 5 mg/kg per day intravenously because of reduced nephrotoxicity compared with
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         [
         <a href="#rid3">
          3
         </a>
         ]. Amphotericin B deoxycholate (0.7 to 1 mg/kg per day intravenously) may be considered in patients without risk factors for renal insufficiency due to its lower cost. (See
         <a class="medical medical_review" href="/z/d/html/2364.html" rel="external">
          "Amphotericin B nephrotoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/476.html" rel="external">
          "Pharmacology of amphotericin B"
         </a>
         .)
        </p>
        <p>
         After the patient has shown a favorable response, therapy can be changed to oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         , 200 mg twice daily. The total duration of therapy should be at least one year and perhaps longer in some patients. Serum levels of itraconazole should be checked after two weeks of therapy to ensure adequate levels.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Mild to moderate disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with mild to moderate pulmonary sporotrichosis should be treated with
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         200 mg orally twice daily for at least 12 months  (
         <a class="graphic graphic_table graphicRef50353" href="/z/d/graphic/50353.html" rel="external">
          table 1
         </a>
         ). Serum levels of itraconazole should be checked after the patient has taken the drug for at least two weeks to ensure adequate levels.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Osteoarticular sporotrichosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Almost all patients with osteoarticular sporotrichosis can be treated with
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         since the infection is usually chronic and localized  (
         <a class="graphic graphic_table graphicRef50353" href="/z/d/graphic/50353.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1-3,30
         </a>
         ]. The minimum dose is 200 mg twice daily, and therapy should continue for at least one year [
         <a href="#rid3">
          3
         </a>
         ]. Serum levels of itraconazole should be checked after the patient has taken the drug for at least two weeks to ensure adequate levels. Even if the infection is cured, functional outcome following arthritis due to
         <em>
          S. schenckii
         </em>
         is often poor. (See
         <a class="local">
          'Choice of antifungal agent'
         </a>
         above.)
        </p>
        <p>
         Amphotericin B is recommended in patients with extensive disease as initial therapy and in those who have not responded to
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         [
         <a href="#rid3">
          3
         </a>
         ]. A lipid formulation is preferred at a dose of 3 to 5 mg/kg per day intravenously because of reduced nephrotoxicity compared with
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         [
         <a href="#rid3">
          3
         </a>
         ]. Amphotericin B deoxycholate (0.7 to 1 mg/kg per day intravenously) may be considered in patients without risk factors for renal insufficiency due to its lower cost. (See
         <a class="medical medical_review" href="/z/d/html/2364.html" rel="external">
          "Amphotericin B nephrotoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/476.html" rel="external">
          "Pharmacology of amphotericin B"
         </a>
         .)
        </p>
        <p>
         After the patient has shown a favorable response, therapy can be changed to oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         , 200 mg twice daily.
        </p>
        <p>
         Intraarticular amphotericin B has been used but is rarely required [
         <a href="#rid31">
          31
         </a>
         ]. Saturated solution of potassium iodide (SSKI), which has efficacy in lymphocutaneous and cutaneous disease, is ineffective in osteoarticular sporotrichosis [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Meningeal sporotrichosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amphotericin B is the drug of choice for meningeal sporotrichosis  (
         <a class="graphic graphic_table graphicRef50353" href="/z/d/graphic/50353.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid32">
          32
         </a>
         ]. A lipid formulation (5 mg/kg per day intravenously for four to six weeks) is preferred because of reduced nephrotoxicity compared with
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'Choice of antifungal agent'
         </a>
         above.)
        </p>
        <p>
         Step-down therapy with oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         , 200 mg twice daily, should be used after initial therapy with amphotericin B is completed. A total of at least 12 months of therapy is required, and for patients with AIDS or ongoing immunosuppression from another cause, chronic suppression with 200 mg itraconazole daily is recommended [
         <a href="#rid3">
          3
         </a>
         ]. Serum levels of itraconazole should be checked after the patient has taken the drug for at least two weeks to ensure adequate levels.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Disseminated sporotrichosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of disseminated sporotrichosis includes initial therapy with intravenous amphotericin B followed by step-down therapy with an oral agent after they have shown a favorable response. There are no clinical trials evaluating therapy of disseminated sporotrichosis, so recommendations are based upon case reports [
         <a href="#rid33">
          33-35
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial therapy
         </strong>
         – For patients with disseminated sporotrichosis, especially those who have visceral involvement, we suggest initial treatment with a lipid formulation of amphotericin B (3 to 5 mg/kg per day intravenously)  (
         <a class="graphic graphic_table graphicRef50353" href="/z/d/graphic/50353.html" rel="external">
          table 1
         </a>
         ). We prefer liposomal amphotericin rather than
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         because of reduced nephrotoxicity [
         <a href="#rid3">
          3
         </a>
         ]; amphotericin B deoxycholate (0.7 to 1 mg/kg per day intravenously) may be considered in patients without risk factors for renal insufficiency due to its lower cost.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one study, patients who had dissemination confined to the skin responded to
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         without initial amphotericin B treatment [
         <a href="#rid36">
          36
         </a>
         ]; however, data are limited, and itraconazole should generally be used as step-down therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Step-down therapy
         </strong>
         – Patients who have received initial therapy with an amphotericin B formulation can transition to step-down therapy with oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         (200 mg twice daily) after they have shown a favorable response. Serum levels of itraconazole should be checked at least two weeks into therapy to ensure adequate levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A total of at least 12 months of therapy is required and chronic suppression should be considered for patients with AIDS or ongoing immunosuppression from another cause [
         <a href="#rid3">
          3
         </a>
         ]. Suppressive therapy may be discontinued in patients with HIV who are taking antiretroviral therapy, have been treated with
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         for at least one year, and have had CD4 counts &gt;200 cells/microL for more than one year [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2768183011">
         <span class="h1">
          ADDITIONAL CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Treatment of pregnant persons
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnant persons should be managed in conjunction with an infectious diseases specialist since azoles should generally be avoided during pregnancy due to their teratogenicity. A discussion of the risks of using azoles during pregnancy is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/115170.html" rel="external">
          "Candida vulvovaginitis in adults: Treatment of acute infection", section on 'Pregnancy'
         </a>
         .)
        </p>
        <p>
         Local hyperthermia can be used during pregnancy for those with cutaneous sporotrichosis [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="local">
          'Lymphocutaneous and cutaneous sporotrichosis'
         </a>
         above.)
        </p>
        <p>
         For those with severe sporotrichosis, a lipid formulation of amphotericin B (3 to 5 mg/kg per day intravenously) is suggested because of reduced nephrotoxicity compared with
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         (
         <a class="graphic graphic_table graphicRef50353" href="/z/d/graphic/50353.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3,37
         </a>
         ]. Amphotericin B deoxycholate (0.7 to 1 mg/kg per day intravenously) may be considered in patients without risk factors for renal insufficiency due to its lower cost. (See
         <a class="medical medical_review" href="/z/d/html/2364.html" rel="external">
          "Amphotericin B nephrotoxicity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/476.html" rel="external">
          "Pharmacology of amphotericin B"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Treatment of children
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with cutaneous or lymphocutaneous sporotrichosis, oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         6 to 10 mg/kg up to a maximum dose of 400 mg daily is recommended  (
         <a class="graphic graphic_table graphicRef50353" href="/z/d/graphic/50353.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3,38
         </a>
         ]. Saturated solution of potassium iodide may be used as an alternative at a dose of one drop in milk or juice three times daily and increased weekly as tolerated to a maximum of one drop per kg or 40 to 50 drops three times daily, whichever is lower [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         For disseminated sporotrichosis, intravenous
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         0.7 mg/kg daily should be given initially and can be followed by oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         6 to 10 mg/kg up to a maximum of 400 mg daily once clinical improvement has occurred [
         <a href="#rid3">
          3
         </a>
         ]. For patients who require a prolonged course of intravenous therapy, such as those with meningeal sporotrichosis, we suggest a lipid formulation of amphotericin B at a dose of 3 to 5 mg/kg per day, which is less nephrotoxic than amphotericin B deoxycholate.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For lymphocutaneous and cutaneous sporotrichosis, oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         200 mg once daily is the drug of choice and should be administered for two to four weeks after all lesions have resolved, usually three to six months. Patients who don't respond to itraconazole at 200 mg/day should be given one of the following alternatives: oral itraconazole at 200 mg twice daily,
         <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">
          terbinafine
         </a>
         500 mg twice daily, or saturated solution of potassium iodide. (See
         <a class="local">
          'Lymphocutaneous and cutaneous sporotrichosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For severe pulmonary sporotrichosis, a lipid formulation of amphotericin B should be used initially. After the patient has shown a favorable response, therapy can be changed to oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         , 200 mg twice daily to complete at least 12 months of therapy. For mild to moderate pulmonary sporotrichosis, oral itraconazole can be given at a dose of 200 mg twice daily for at least 12 months of therapy. (See
         <a class="local">
          'Pulmonary sporotrichosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Osteoarticular sporotrichosis can generally be treated with oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         200 mg twice daily for at least 12 months since the infection is usually chronic and localized. Amphotericin B is recommended in patients with extensive disease as initial therapy and in those who have not responded to itraconazole. After the patient has shown a favorable response, therapy can be changed to oral itraconazole, 200 mg twice daily. (See
         <a class="local">
          'Osteoarticular sporotrichosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For meningeal sporotrichosis, a lipid formulation of amphotericin B (5 mg/kg per day intravenously for four to six weeks) is the drug of choice. Step-down therapy with oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         , 200 mg twice daily, should be used after initial therapy with amphotericin B is completed and therapy should continue for at least 12 months. For patients with AIDS or ongoing immunosuppression from another cause, chronic suppression with 200 mg itraconazole daily is recommended. (See
         <a class="local">
          'Meningeal sporotrichosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For disseminated sporotrichosis, we suggest a lipid formulation of amphotericin B (3 to 5 mg/kg per day intravenously). Step-down therapy with oral
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         , 200 mg twice daily, should be started after the patient has shown a favorable response and therapy should be continued for at least 12 months. Chronic suppression should be considered for patients with AIDS or ongoing immunosuppression from another cause. (See
         <a class="local">
          'Disseminated sporotrichosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum levels of
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         should be checked after the patient has taken the drug for at least at least two weeks for pulmonary, osteoarticular, meningeal, and disseminated sporotrichosis to ensure adequate levels. (See
         <a class="local">
          'Pulmonary sporotrichosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For pregnant women with severe sporotrichosis, a lipid formulation of amphotericin B (3 to 5 mg/kg per day intravenously) is suggested. Azoles should not be given during pregnancy due to their teratogenicity. (See
         <a class="local">
          'Treatment of pregnant persons'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The treatment of sporotrichosis in children is similar to that in adults, although the dosing differs. (See
         <a class="local">
          'Treatment of children'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis 1995; 21:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharkey-Mathis PK, Kauffman CA, Graybill JR, et al. Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group. Am J Med 1993; 95:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kauffman CA, Bustamante B, Chapman SW, et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galhardo MC, De Oliveira RM, Valle AC, et al. Molecular epidemiology and antifungal susceptibility patterns of Sporothrix schenckii isolates from a cat-transmitted epidemic of sporotrichosis in Rio de Janeiro, Brazil. Med Mycol 2008; 46:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarado-Ramírez E, Torres-Rodríguez JM. In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods. Antimicrob Agents Chemother 2007; 51:2420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kauffman CA, Pappas PG, McKinsey DS, et al. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infect Dis 1996; 22:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horsburgh CR Jr, Cannady PB Jr, Kirkpatrick CH. Treatment of fungal infections in the bones and joints with ketoconazole. J Infect Dis 1983; 147:1064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calhoun DL, Waskin H, White MP, et al. Treatment of systemic sporotrichosis with ketoconazole. Rev Infect Dis 1991; 13:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marimon R, Serena C, Gené J, et al. In vitro antifungal susceptibilities of five species of sporothrix. Antimicrob Agents Chemother 2008; 52:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigues AM, de Hoog GS, de Cássia Pires D, et al. Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis. BMC Infect Dis 2014; 14:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Zhan P, Jiang Q, et al. Prevalence and antifungal susceptibility of Sporothrix species in Jiangxi, central China. Med Mycol 2019; 57:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Silva F, Capilla J, Mayayo E, Guarro J. Efficacy of posaconazole in murine experimental sporotrichosis. Antimicrob Agents Chemother 2012; 56:2273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomson J, Trott DJ, Malik R, et al. An atypical cause of sporotrichosis in a cat. Med Mycol Case Rep 2019; 23:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bunce PE, Yang L, Chun S, et al. Disseminated sporotrichosis in a patient with hairy cell leukemia treated with amphotericin B and posaconazole. Med Mycol 2012; 50:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paixão AG, Galhardo MCG, Almeida-Paes R, et al. The difficult management of disseminated Sporothrix brasiliensis in a patient with advanced AIDS. AIDS Res Ther 2015; 12:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           He Y, Ma C, Fung M, Fitzmaurice S. Disseminated cutaneous sporotrichosis presenting as a necrotic facial mass: Case and review. Dermatol Online J 2017; 23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson GR 3rd, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010; 170:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A, Abreu DPB, Almeida-Paes R, et al. Multicenter, International Study of MIC/MEC Distributions for Definition of Epidemiological Cutoff Values for Sporothrix Species Identified by Molecular Methods. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Restrepo A, Robledo J, Gómez I, et al. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol 1986; 122:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Lima Barros MB, Schubach AO, de Vasconcellos Carvalhaes de Oliveira R, et al. Treatment of cutaneous sporotrichosis with itraconazole--study of 645 patients. Clin Infect Dis 2011; 52:e200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conti Díaz IA, Civila E, Gezuele E, et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 1992; 35:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman SW, Pappas P, Kauffmann C, et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 2004; 47:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabezas C, Bustamante B, Holgado W, Begue RE. Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide. Pediatr Infect Dis J 1996; 15:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kauffman CA. Sporotrichosis. Clin Infect Dis 1999; 29:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macedo PM, Lopes-Bezerra LM, Bernardes-Engemann AR, Orofino-Costa R. New posology of potassium iodide for the treatment of cutaneous sporotrichosis: study of efficacy and safety in 102 patients. J Eur Acad Dermatol Venereol 2015; 29:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hiruma M, Kawada A, Noguchi H, et al. Hyperthermic treatment of sporotrichosis: experimental use of infrared and far infrared rays. Mycoses 1992; 35:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pluss JL, Opal SM. Pulmonary sporotrichosis: review of treatment and outcome. Medicine (Baltimore) 1986; 65:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiwari A, Malani AN. Primary pulmonary sporotrichosis: Case report and review of the literature. Infect Dis Clin Pract 2012; 20:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aung AK, Teh BM, McGrath C, Thompson PJ. Pulmonary sporotrichosis: case series and systematic analysis of literature on clinico-radiological patterns and management outcomes. Med Mycol 2013; 51:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winn RE, Anderson J, Piper J, et al. Systemic sporotrichosis treated with itraconazole. Clin Infect Dis 1993; 17:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downs NJ, Hinthorn DR, Mhatre VR, Liu C. Intra-articular amphotericin B treatment of Sporothrix schenckii arthritis. Arch Intern Med 1989; 149:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kauffman CA. Central Nervous System Infection with Other Endemic Mycoses: Rare Manifestation of Blastomycosis, Paracoccidioidomycosis, Talaromycosis, and Sporotrichosis. J Fungi (Basel) 2019; 5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottlieb GS, Lesser CF, Holmes KK, Wald A. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists. Clin Infect Dis 2003; 37:838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rotz LD, Slater LN, Wack MF, et al. Disseminated sporotrichosis with meningitis in a patient with AIDS. Infect Dis Clin Prac 1996; 5:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           al-Tawfiq JA, Wools KK. Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection. Clin Infect Dis 1998; 26:1403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freitas DF, de Siqueira Hoagland B, do Valle AC, et al. Sporotrichosis in HIV-infected patients: report of 21 cases of endemic sporotrichosis in Rio de Janeiro, Brazil. Med Mycol 2012; 50:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costa RO, Bernardes-Engemann AR, Azulay-Abulafia L, et al. Sporotrichosis in pregnancy: case reports of 5 patients in a zoonotic epidemic in Rio de Janeiro, Brazil. An Bras Dermatol 2011; 86:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tirado-Sánchez A, Bonifaz A. Sporotrichosis in Children: an Update. Curr Fungal Infect Rep 2016; 10:107.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2431 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8645851" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Old and new therapies for sporotrichosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8396321" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17968818" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18324493" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Molecular epidemiology and antifungal susceptibility patterns of Sporothrix schenckii isolates from a cat-transmitted epidemic of sporotrichosis in Rio de Janeiro, Brazil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17438048" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8824965" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6304204" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Treatment of fungal infections in the bones and joints with ketoconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2017630" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Treatment of systemic sporotrichosis with ketoconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18039919" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : In vitro antifungal susceptibilities of five species of sporothrix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24755107" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30657948" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Prevalence and antifungal susceptibility of Sporothrix species in Jiangxi, central China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22330929" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Efficacy of posaconazole in murine experimental sporotrichosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30723664" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : An atypical cause of sporotrichosis in a cat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21612561" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Disseminated sporotrichosis in a patient with hairy cell leukemia treated with amphotericin B and posaconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25949269" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The difficult management of disseminated Sporothrix brasiliensis in a patient with advanced AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29469701" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Disseminated cutaneous sporotrichosis presenting as a necrotic facial mass: Case and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20524153" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28739796" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Multicenter, International Study of MIC/MEC Distributions for Definition of Epidemiological Cutoff Values for Sporothrix Species Identified by Molecular Methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3006602" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Itraconazole therapy in lymphangitic and cutaneous sporotrichosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21628477" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Treatment of cutaneous sporotrichosis with itraconazole--study of 645 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1335550" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Treatment of human cutaneous sporotrichosis with itraconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14998402" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8866807" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10476718" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Sporotrichosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25229626" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : New posology of potassium iodide for the treatment of cutaneous sporotrichosis: study of efficacy and safety in 102 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1302801" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hyperthermic treatment of sporotrichosis: experimental use of infrared and far infrared rays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3517551" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Pulmonary sporotrichosis: review of treatment and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Primary pulmonary sporotrichosis: Case report and review of the literature
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23286352" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pulmonary sporotrichosis: case series and systematic analysis of literature on clinico-radiological patterns and management outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8399869" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Systemic sporotrichosis treated with itraconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2705851" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Intra-articular amphotericin B treatment of Sporothrix schenckii arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31323746" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Central Nervous System Infection with Other Endemic Mycoses: Rare Manifestation of Blastomycosis, Paracoccidioidomycosis, Talaromycosis, and Sporotrichosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12955647" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Disseminated sporotrichosis with meningitis in a patient with AIDS
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9636870" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21859385" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Sporotrichosis in HIV-infected patients: report of 21 cases of endemic sporotrichosis in Rio de Janeiro, Brazil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22147042" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Sporotrichosis in pregnancy: case reports of 5 patients in a zoonotic epidemic in Rio de Janeiro, Brazil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Sporotrichosis in Children: an Update
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
